MINNEAPOLIS, Jan. 30 /PRNewswire-FirstCall/ -- ATS Medical, Inc. is an exhibitor-participant at the 42nd Annual Meeting of the Society of Thoracic Surgeons (STS). The event runs January 30-February 1, 2006 at McCormick Place in Chicago.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO )
The goal of ATS Medical's participation in this year's STS Annual Meeting is to showcase our expanding product portfolio. The ATS Simulus(TM) annuloplasty product line, designed for the heart valve repair market segment which is estimated at $115 million and growing, is being introduced at the meeting. The alliance of Quality Assured Services (QAS) home monitoring service for patients on oral anticoagulation therapy will also be featured.
The widely used ATS Open Pivot(R) Heart Valve, the ATS Simulus(TM) annuloplasty line and the proposed 3F Therapeutics acquisition place ATS Medical firmly in the major segments of the heart valve therapy market. The market is estimated to be $1 billion and growing.
"As always, we are gratified to be an active participant in the STS Annual Meeting. We are particularly enthused that this year's meeting gives us the opportunity to reveal to our STS friends the expanding line of ATS Medical products and services focusing on the needs of the cardiac surgeon," said Michael D. Dale, Chairman, President and CEO of ATS Medical.
The co-marketing alliance with QAS is designed to provide home monitoring for patients on oral anticoagulation therapy. Oral anticoagulants are employed to systematically manage thrombotic disorders by decreasing the clotting ability of blood and to prevent unwanted clots. The QAS alliance with ATS Medical will make referral information more readily available to cardiac surgeons, cardiologists and general practitioners whose patients require monitoring of oral anticoagulant use.
About ATS Medical
ATS Medical, Inc. manufactures and markets products and services focused on cardiac surgery. The company, global in scope, has been headquartered in Minneapolis since its founding in 1991. More than 100,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(TM) annuloplasty products for heart valve repair, Surgi-Frost(R) and Frost-Byte(TM) products for surgical cryoablation of cardiac arrhythmias, RTI-Cardiovascular for allograft tissue services, QAS home monitoring services for anticoagulation therapy and the development of PARSUS blood filtration technology. The ATS Medical web site is http://www.atsmedical.com .
More information about the STS annual meeting can be found at http://www.sts.org .
Safe Harbor
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission to its Form 10-K for the year ended December 31, 2004.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comATS Medical, Inc.CONTACT: Michael Dale, President and CEO, +1-763-557-2224, or Jack Judd,CFO, +1-763-557-2222, both of ATS Medical, Inc.; or Investors, DouglasSherk, +1-415-652-9100, or Jennifer Beugelmans, +1-415-896-6820; or Media,Steve DiMattia, +1-646-277-8706, or Sheryl Seapy, +1-949-608-0841, all forATS Medical, Inc.
